서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 19 of 19

Issue DateTitle / Author(s) / CitationFileAltmetrics
2014-07
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy
DOI
2014-12
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score
DOI
2015-01
An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients
DOI
2015-03
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)
DOI
2015-06
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Sim, Sung Hoon; Kim, Yu Jung; Kim, Se Hyun; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok

Journal of Cancer Research and Clinical Oncology, Vol.141 No.6, pp.1073-1081

DOI
2015-10
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
view fileDOI
2017-04
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
view fileDOI
2017-09
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
DOI
2018-03
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
view fileDOI
2018-03
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
view fileDOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-08
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
1